Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clarus Therapeutics Holdings, Inc.CRXT · Entity 126356 | Director | June 07, 2022 | June 09, 2022 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clarus Therapeutics Holdings, Inc.
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,766 |
Reported balance
After 2022-06-07 transaction · row 1
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 1,922 · Balance 5,766 F1: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2032-06-06 | Direct | 4,805 |
Reported balance
After 2022-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-07 · Grant · Acquired 4,805 · Balance 4,805 F2: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
F2: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
Verrica Pharmaceuticals Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-06-04 | Direct | 16,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001257544-26-000002 · form4-06092026_040601.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001415889-25-016289 · form4-06092025_040605.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015961 · form4-06072024_040613.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 13:02 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-036145 · doc4.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2033-06-07 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:18 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-22-036298 · doc4.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:06 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantStock Option (Right to Buy) · Derivative | 4,805 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0000899243-22-021761 · doc4.xml · derivative · entry 2 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Common Stock · 4,805 shares Expires 2032-06-06 F2 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:06 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantCommon Stock | 1,922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-021761 · doc4.xml · nonDerivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766 F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document |
| December 12, 2021 Filed Dec 14, 2021 19:03 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantStock Option (Right to Buy) · Derivative | 9,610 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0000899243-21-048213 · doc4.xml · derivative · entry 2 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 Underlying: Common Stock · 9,610 shares Expires 2031-12-11 F2 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in equal annual installments over a period of three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document |
| December 12, 2021 Filed Dec 14, 2021 19:03 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantCommon Stock | 3,844 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-048213 · doc4.xml · nonDerivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,844 F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 3,844 shares on 12/12/2021, which vests in equal annual installments over three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:58 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 5,834 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-040267 · doc4.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2031-06-09 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 17, 2021 20:36 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 8,109 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041449 · doc4a.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Underlying: Common Stock · 8,109 shares Expires 2031-06-09 F1 · shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F1 · balance_after: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:49 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantOption Grant (right to buy) · Derivative | 5,834 | $0.00 Strike: $11.38 | $0.00 |
DisclosureSEC source: 0001209191-20-036318 · doc4.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2030-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 11, 2020 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:53 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 5,834 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001209191-19-037166 · doc4.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 12, 2019 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:29 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 17,502 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038316 · doc4.xml · derivative · entry 1 PRYGOCKI MARK A SR · CIK 0001257544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 17,502 shares Expires 2028-06-14 F1 · derivative.exercise_date: 1/3 of the total shares subject to the option shall vest on June 14, 2019 and 1/36th of the total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.